August 2, 2024 07:09 AM EDTUpdated August 2, 10:34 PM
Deals
R&D
Cell/Gene Tx

Gala­pa­gos paus­es blood can­cer CAR-T ther­a­py tri­al due to one Parkin­son­ism event

Ayisha Sharma

News Reporter

Gala­pa­gos has tem­porar­i­ly stopped en­rolling pa­tients in­to an ear­ly-phase test in pa­tients with mul­ti­ple myelo­ma af­ter a neu­ro­log­i­cal is­sue was raised. Else­where, the biotech ex­pand­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times